Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (1245)	6/26/1998 4:51:00 PM
From: Ken Salaets	Read Replies (2) \| Respond to of 4634

Nice one, Bill. Only a fool would draw that conclusion. Thank you for verifying the obvious! LOL! The only fraud indirectly associated w/Tava is an SI (im)poster who goes by the name of Bill Wexler. Hope you actually follow your own advice. Should make for a nice weekend, eh? LOL again!

To: Bill Wexler who wrote (1245)	6/26/1998 4:54:00 PM
From: Daniel Miller	Read Replies (1) \| Respond to of 4634

I have a question. If the stock you short goes out of business that is good right? Are you able to short penny stocks?

To: Bill Wexler who wrote (1245)	6/26/1998 4:58:00 PM
From: Hank	Read Replies (1) \| Respond to of 4634

Bill, I would like to recommend a possible future addition to your DOOM index if I may be so bold. Viropharma (VPHM). This is a small biotech company that specializes in the discovery of drugs that inhibit RNA viruses. They have one lead compound in clinical trials (can't remember the name) that is supposed to work against Rhino virus (the cause of the common cold). The problem is that there are over 100 different rhino viruses and their drug only works against less than half of them in the laboratory. Consequently, they are trying to pawn this drug off as a treatment for viral meningitis and for severe asthmatics with colds. Both very narrow markets with low profit potential. Furthermore, I hear that they have been trying to out license potential flu and hepatitis C drugs to big drug firms for development. The word is that in other companies hands, these drugs are inactive even though VPHM has claimed activity in the lab. A sure sign they trying to scam useless drugs for big drug support much the same way ZONA successfully duped SGP. They have a fair amount of cash in the bank but their profit potential is bleak IMHO. They are currently trading in the 20's but they are barely worth $5 given the lack of a block buster drug candidate. I've also noticed that their short interest has jumped dramatically in the last month to 150,000 which is about 4 or 5 times what it was in the previous month. Just one to keep in mind. My short term price target for this stock is $10 or less. Hank

To: Bill Wexler who wrote (1245)	6/26/1998 4:59:00 PM
From: Cosmo Daisey	Read Replies (3) \| Respond to of 4634

Dr. Wexler, Keep you eye on TAVA on Monday during the CEO visit on CNBC. I have done very well shorting the stocks of the guest CEO's. The reason for the appearance is to create some demand so the insiders can unload some stock. The insiders will have until July 10 to file and I will bet real money that's what the guest appearance is all about. Volume will be big on monday, short some more. Tuesday it's back to business as usual. Dr. Daisey